Filtered By:
Drug: Zivast

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 101 results found since Jan 2013.

l -Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats
Conclusions Coadministration of l-carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin while antagonizing myopathy in ovariectomized rats. This could be valuable in treatment of osteoporotic patients. However, further confirmatory studies are needed.
Source: Journal of Zhejiang University. Science. B. - January 1, 2016 Category: Universities & Medical Training Source Type: research

L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats.
CONCLUSIONS: Co-administration of L-carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin while antagonizing myopathy in ovariectomized rats. This could be valuable in treatment of osteoporotic patients. However, further confirmatory studies are needed. PMID: 26739525 [PubMed - in process]
Source: J Zhejiang Univ Sci ... - January 1, 2016 Category: Science Authors: Murad HA Tags: J Zhejiang Univ Sci B Source Type: research

The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects
Statins reduce atherosclerotic events and cardiovascular mortality. Their side effects include memory loss, myopathy, cataract formation, and increased risk of diabetes. As cardiovascular mortality relates to plaque instability, which depends on the integrity of the fibrous cap, we hypothesize that the inhibition of the potential of mesenchymal stem cells (MSCs) to differentiate into macrophages would help to explain the long known, but less understood "non-lipid-associated" or pleiotropic benefit of statins on cardiovascular mortality. In the present investigation, MSCs were treated with atorvastatin or pravastatin at cli...
Source: AJP: Cell Physiology - October 15, 2015 Category: Cytology Authors: Izadpanah, R., Schachtele, D. J., Pfnur, A. B., Lin, D., Slakey, D. P., Kadowitz, P. J., Alt, E. U. Tags: CALL FOR PAPERS Source Type: research

Multi-drug intoxication fatality involving atorvastatin: a case report
Antihypertensives and hypolipidemics belong among the most commonly prescribed drugs. Despite providing beneficial effects in terms of decreased long-term cardiovascular morbidity and mortality, these pharmaceuticals may pose a high risk of death, particularly when administered in parallel and when largely overdosed. Intoxications by one or more of these medications were documented in a number of case reports [1–9] and reviews [10,11]. The most noxious adverse effects of antihypertensives are due to arrhythmia and excessive vasodilation with hypotension, whereas the use of hypolipidemics (statins) is monitored to reduce ...
Source: Forensic Science International - October 9, 2015 Category: Forensic Medicine Authors: Lubica Cibickova, Tomas Caran, Martin Dobias, Peter Ondra, Viktor Vorisek, Norbert Cibicek Tags: Case Report Source Type: research

Myopathy induced by statin‑ezetimibe combination: Evaluation of potential risk factors
We report a case of myalgia with elevated serum creatinine phosphokinase in a patient after 2 months of therapy with fixed dose combination of atorvastatin and ezetimibe (10 mg each). At the time of the event, patient was undertaking moderate physical exertion in the form of brisk walking for 30–40 min a day and was detected to have low serum Vitamin D levels. The adverse event resolved after stopping atorvastatin-ezetimibe combination therapy. Potential risk factors, such as physical exertion and Vitamin D deficiency, co-existent in dyslipidemic patients, may exacerbate myopathy potential of these drugs, and ...
Source: Indian Journal of Pharmacology - September 15, 2015 Category: Drugs & Pharmacology Authors: Ballari BrahmachariSuparna Chatterjee Source Type: research

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case–Control Studies
This study aimed to investigate this genetic association. Databases of PubMed, EMBASE, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database, and Wanfang Data were searched till June 17, 2015. Case-control studies investigating the association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk were included. The Newcastle–Ottawa Scale (NOS) was used for assessing the quality of included studies. Data were pooled by odds ratios (ORs) and their 95% confidence intervals (CIs). Nine studies with 1360 cases and 3082 controls wer...
Source: Medicine - September 1, 2015 Category: Internal Medicine Tags: Research Article: Meta-Analysis of Observational Studies in Epidemiology (MOOSE Compliant) Source Type: research

The Impact of Statins on Biological Characteristics of Stem Cells Provides a Novel Explanation for Their Pleotropic Beneficial and Adverse Clinical Effects.
Abstract Statins reduce atherosclerotic events and cardiovascular mortality. Their side effects include memory loss, myopathy, cataract formation, and increased risk of diabetes. As cardiovascular mortality relates to plaque instability, which depends on the integrity of the fibrous cap, we hypothesize that the inhibition of the potential of Mesenchymal Stem Cells (MSCs) to differentiate into macrophages would help to explain the long known, but less understood "Non Lipid Associated" or pleiotropic benefit of statins on cardiovascular mortality. In the present investigation, MSCs were treated with atorvastatin or ...
Source: American Journal of Physiology. Cell Physiology - July 29, 2015 Category: Cytology Authors: Izadpanah R, Schächtele DJ, Pfnür AB, Lin D, Slakey DP, Kadowitz PJ, Alt EU Tags: Am J Physiol Cell Physiol Source Type: research

Clinical Picture Immune-mediated necrotising myopathy linked to statin use
In December, 2013, a 59-year-old man presented to the Neurology Department with progressive pelvic girdle myalgia and proximal weakness so severe that he needed help walking. His myalgia had started in March, 2012, 4 months after starting atorvastatin, and had persisted despite discontinuation of the statin in September, 2013. On examination we noted severe proximal paraparesis. Laboratory tests revealed substantially raised serum creatine kinase concentration (3453 U/L, normal range
Source: LANCET - June 11, 2015 Category: Journals (General) Authors: Stefan Kipfer, Susanna Frigerio, Jürgen Hench, Audrey Aussy, Olivier Boyer Tags: Clinical Picture Source Type: research

Role of genetic factors in statins side-effects.
In conclusion, the picture of putative pharmacogenetic modulation of statins safety is reaching a growing body of evidence for translation into clinical practice but more specific studies for each single statin, in different clinical settings, both from genome-wide or competitive candidate genes evaluation, are needed before describing a definitive class-risk profile. PMID: 22524173 [PubMed - indexed for MEDLINE]
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population.
CONCLUSIONS In Czech patients treated with low statin doses, there is no association between SLCO1B1 gene polymorphism and risk of myalgia/myopathy. PMID: 25992810 [PubMed - in process]
Source: Medical Science Monitor - May 22, 2015 Category: Research Tags: Med Sci Monit Source Type: research

The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity
In conclusion, this study highlights the importance of the AKT/mTOR signaling pathway in statin-induced myotoxicity and reveals potential drug targets for treatment of patients with statin-associated myopathies.
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - May 17, 2015 Category: Molecular Biology Source Type: research

Atorvastatin Increases miR‐124a Expression: A Mechanism of GAMT Modulation in Liver Cells
This study aimed to investigate the cytotoxicity and the effect of atorvastatin on microRNA expression in HepG2 cells. The methylthiazol tetrazolium assay was used to assess hepatocyte viability and at 20µM atorvastatin (24h) treatment were 82 ± 1.5% viable (p = 0.0002). Levels of intracellular ATP in cells treated with 20µM atorvastatin were reduced by 1.25‐fold, p = 0.002. Cytotoxicity, measured by the release of intracellular lactate dehydrogenase, was increased from 0.95 ± 0.29 units in control cells to 1.12 ± 0.02 units (p = 0.002) in atorvastatin treated cells. A panel of 84‐miRNA spe...
Source: Journal of Cellular Biochemistry - April 28, 2015 Category: Biochemistry Authors: Alisa Phulukdaree, Devapregasan Moodley, Sajidah Khan, Anil A Chuturgoon Tags: Article Source Type: research

The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity.
In conclusion, this study highlights the importance of the AKT/mTOR signaling pathway in statin-induced myotoxicity and reveals potential drug targets for treatment of patients with statin-associated myopathies. PMID: 25913013 [PubMed - as supplied by publisher]
Source: Biochimica et Biophysica Acta - April 23, 2015 Category: Biochemistry Authors: Bonifacio A, Sanvee G, Bouitbir J, Krähenbühl S Tags: Biochim Biophys Acta Source Type: research

Statins and Myotoxic Effects Associated With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies: An Observational Study in Japan
Abstract: Statins have a variety of myotoxic effects and can trigger the development of inflammatory myopathies or myasthenia gravis (MG) mediated by immunomodulatory properties. Autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) have been identified in patients with statin-associated myopathy. The purpose of the present study is to develop an enzyme-linked immunosorbent assay (ELISA) of anti-HMGCR antibodies and to elucidate the clinical significance of anti-HMGCR antibodies in Japanese patients with inflammatory myopathies or MG. We enrolled 75 patients with inflammatory myopathies, who were all ne...
Source: Medicine - January 1, 2015 Category: Internal Medicine Tags: Article: Observational Study Source Type: research

Increased dosage of cyclosporine induces myopathy with increased seru creatine kinase in an elderly patient on chronic statin therapy
Summary What is known and objectiveThe concomitant administration of atorvastatin and cyclosporine has been shown to increase the serum concentration of 3‐hydroxy‐3‐methylglutaryl coenzyme A, which may be associated with the elevation of creatine kinase and an increased risk of myopathy. Our objective is to report on a case of statin‐induced myopathy associated with concomitant use of cyclosporine and other contributing factors. Case summaryAn 88‐year‐old Chinese male patient with comorbidities received polypharmacy treatment, including atorvastatin and cyclosporine. After the dosage of cyclosporine was increas...
Source: Journal of Clinical Pharmacy and Therapeutics - December 1, 2014 Category: Drugs & Pharmacology Authors: L. Mo, J. He, Q. Yue, B. Dong, X. Huang Tags: Case Report Source Type: research